Oral tranexamic acid to reduce blood loss in patients undergoing total knee replacements

Phase 2

Recruiting

• Conditions: Total knee replacement; Surgery - Other surgery; Blood - Other blood disorders; Musculoskeletal - Osteoarthritis

• Registration Number: ACTRN12617000617369
• Lead Sponsor: John Flynn Private Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-05-01
• Last Update Posted: 16 September 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Participants undergoing total knee replacements at John Flynn Hospital

Exclusion Criteria

Patients currently on anticoagulant therapy, patients with bleeding disorders, patients at high risk of deep vein thrombosis (i.e.Factor V Leiden, past history of deep vein thrombosis)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome will be blood loss due to surgery.[This data will be determined by the amount of blood loss in theatre and the volume collected from the joint drain at ten hours post-surgery.]

Secondary Outcome Measures

Name	Time	Method
Safety will be measured by the incidence of adverse events attributed to TXA, in particular the incidence of DVT. [This will be determined by means of Doppler ultrasound at six weeks post-surgery.]